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Study Objective. To assess the effectiveness, safety, and cost of empiric
treatment of febrile neutropenia before and after implementing an algorithm
in which voriconazole was substituted for liposomal amphotericin B (L-AmB).
Design. Retrospective cohort analysis.
Setting. An 850-bed tertiary care hospital, which is also a referral site for
patients with acute leukemia.
Patients. Fifty-five adult patients who started empiric antifungal therapy for
febrile neutropenia between January 1, 2002, and December 31, 2003,
encompassing 58 treatment episodes (defined as a hospitalization during
which empiric antifungal therapy was administered).
Measurements and Main Results. Medical charts, including patients’
pharmacy and laboratory data, were reviewed.  Twenty-six and 32 episodes
of L-AmB and voriconazole use, respectively, were identified.  No
significant differences between the L-AmB and voriconazole groups were
noted at baseline.  Rates of fever resolution (54% vs 59%, p=0.791) and
breakthrough invasive fungal infections (11% vs 12%, p>0.999) were
similar for the L-AmB and voriconazole episodes.  Premature drug
discontinuation due to the prescriber’s perceived lack of efficacy occurred
most frequently in the voriconazole group (25% vs 8%, p=0.160).  Survival
was significantly higher in the voriconazole than in the L-AmB group
(100% vs 77%, p=0.006).  Adverse effects that were significantly more
common in the L-AmB group than in the voriconazole group were elevated
serum creatinine levels (27% vs 3%, p=0.017) and electrolyte disturbances
(19% vs 0%, p=0.014).  Adverse effects reported more frequently in the
voriconazole group than in the L-AmB group were visual disturbances (9%
vs 0%, p=0.245) and elevated hepatic enzyme levels (9% vs 8%, p>0.999).
Mean drug expenditures/episode for initial empiric antifungal therapy were
lower for voriconazole than for L-AmB ($1593 vs $4144, or $153 vs
$380/day).
Conclusion. Our institution’s algorithm incorporating voriconazole into
the empiric management of febrile neutropenia was associated with
effectiveness outcomes comparable to those observed with L-AmB as well
as a lower frequency of adverse effects and overall expenditures for
antifungal drugs.
Key Words: voriconazole, liposomal amphotericin B, L-AmB, febrile
neutropenia, antifungals, hematology, empiric therapy.
(Pharmacotherapy 2007;27(7):970–979)
VORICONAZOLE VS LIPOSOMAL AMPHOTERICIN B FOR FEBRILE NEUTROPENIA  Shehab et al
Empiric antifungal therapy with amphotericin
B deoxycholate is considered the standard of care
for patients with febrile neutropenia (< 500
polymorphonuclear neutrophils/mm3) that
persists despite broad-spectrum antibacterial
therapy.1 Liposomal amphotericin B (L-AmB)
has similar effectiveness in patients with febrile
neutropenia and is generally better tolerated than
amphotericin B deoxycholate.  However, it is
associated with a substantially higher acquisition
cost.2, 3 Anecdotal evidence suggests that voricona-
zole, a second-generation azole antifungal agent,
is increasingly being used in lieu of L-AmB as
empiric therapy for febrile neutropenia despite a
lack of data to suggest its equivalency to ampho-
tericin products.4 Voriconazole is active against
most fungi that contribute to invasive fungal
infections observed in immunocompromised
patients, including those due to relatively
uncommon but increasingly important emerging
pathogens such as Scedosporium and Fusarium
species.5–9 Other potential benefits of voriconazole
compared with L-AmB are its availability in oral
formulations, its favorable safety profile, and its
low acquisition cost.4, 10–12
Our institution developed an algorithm in
which voriconazole is the preferred agent for
adult patients who underwent chemotherapy for
hematologic cancer and experienced febrile neu-
tropenia (Figure 1).  Thus, our primary objective
was to assess the impact of substituting voricona-
zole for L-AmB on effectiveness, safety, and cost
in this population.  Our secondary objective was
to characterize how empiric anti-fungal therapy
was being used before (January 1–December 31,
2002) and after (January 1–December 31, 2003)
implementation of the algorithm.
Methods
Study Design, Setting, and Patients
This retrospective cohort study was based on a
review of medical charts including pharmacy and
laboratory data.  It was conducted at the
University of Michigan Hospital, which is an
850-bed tertiary care center.  The hospital is also
a large referral site for patients with acute
leukemia, with more than 70 such patients
admitted annually.  The institutional review
board of the University of Michigan approved
this study; informed consent was not required for
the study due to its retrospective nature.
Patients were eligible if they were at least 18
years old; if they received chemotherapy to treat
leukemia, lymphoma, or another hematologic
cancer; if they had a documented diagnosis of
febrile neutropenia; and if they received empiric
antifungal therapy with L-AmB between January
1 and December 31, 2002 or with voriconazole
between January 1 and December 31, 2003.
Patients were excluded if they had a documented
invasive fungal infection at admission or within
24 hours of first receiving empiric antifungal
therapy.13 Patients who had undergone or were
undergoing hematopoietic stem cell transplan-
tation were also excluded.
Data Collection
To compare the two treatments, L-AmB versus
voriconazole, we collected data according to
episode.  A treatment episode was defined as a
single hospital admission during which a patient
received at least one dose of L-AmB or voriconazole
as the initial empiric antifungal agent; these
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Figure 1. University of Michigan Hospital febrile
neutropenia treatment algorithm.  ANC =  absolute
neutrophil count; L-AmB = liposomal amphotericin B.
ANC ≤ 500 cells/mm3, or ≤ 1000 cells/mm3 with a predicted
drop of ≤ 500 cells/mm3 and persistent fever (single oral
temperature ≥ 101°F or > 100.4°F for > 1 hour) despite
antibiotics, and with no defined etiology
Continue antibiotics
according to hospital
guidelines
Patient with liver dysfunction or
receiving gemtuzumab therapy
Add voriconazole 6 mg/kg i.v. q12h x 2, then
3 mg/kg i.v. q12h x 4, then 200 mg p.o. q12h
Add L-AmB 3 mg/kg i.v. q24h
Persistent fever for 72
hours after initial therapy?
Discontinue voriconazole and start
L-AmB 3 mg/kg i.v. q24h
No
Yes
No Yes
Yes
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episodes were assigned to the L-AmB or
voriconazole group accordingly.
We recorded the patients’ demographic charac-
teristics, primary diagnosis, and chemotherapy
regimens.  Receipt of systemic antifungal
prophylaxis, granulocyte colony-stimulating
factor (filgrastim), and/or granulocyte-macrophage
colony-stimulating factor (sargramostim), as well
as the duration of neutropenia (absolute neutrophil
count < 500 cells/mm3) and fever (temperature ≥
100.4°F [≥ 38°C]) were noted.  Any modifications
to antibacterial regimens within 48 hours before
the start of empiric antifungal therapy were also
documented.
We also recorded the use of antifungal drugs,
including their dosages, durations of therapy,
routes of administration, and any premedication
with acetaminophen, meperidine, or diphen-
hydramine.  The number and fungal etiology (if
available) of all breakthrough invasive fungal
infections were documented.  Breakthrough
invasive fungal infections were further classified
as proven, probable, or possible on the basis of
the Mycoses Study Group criteria for disease
certainty.13 A hematologist-oncologist reviewed
and confirmed these classifications.  Utilization
data were collected for any antifungal agents that
were started if therapy with L-AmB or voricona-
zole was discontinued or if an antifungal agent
was added to L-AmB or voriconazole therapy.
Effectiveness Outcomes
Measures of effectiveness were the resolution
of fever (temperature < 100.4°F [< 38°C] for at
least 24 hrs) during the period of neutropenia, no
discontinuation of an antifungal agent because of
the prescriber’s perceived lack of efficacy before
the patient recovered from neutropenia, absence
of a breakthrough invasive fungal infection
within 7 days after the end of therapy, and
survival within 7 days after the end of therapy.
Safety Outcomes
We documented the following adverse
laboratory effects that occurred during empiric
antifungal therapy:  alkaline phosphatase,
aspartate aminotransferase, alanine amino-
transferase, and bilirubin levels that were 5 times
baseline in patients whose baseline values were
less than 2 times the upper limit of normal (we
noted increases of 3 times baseline when patient’s
baseline values were 2–5 times the upper limit of
normal); and instances of hypokalemia
(potassium concentration ≤ 3.0 mEq/L), hypo-
magnesemia (magnesium concentration ≤ 1.5
mg/dl), and nephrotoxicity (serum creatinine
levels > 1.5 times the patient’s baseline value).
We also documented infusion-related reactions,
such as chills, fever, or a rash that developed as a
direct result of the empiric antifungal agent, as
well as the need for dialysis during empiric
antifungal therapy.  We recorded other adverse
reactions, including visual disturbances, that
occurred during treatment and that were
documented in the medical record.  Finally, we
reported any treatment discontinuation due to a
documented adverse effect or a concern about an
effect.
Composite Outcome
The composite outcome consisted of resolution
of fever during the period of neutropenia, absence
of a breakthrough invasive fungal infection
within 7 days after the end of therapy, no discon-
tinuation of antifungal therapy secondary to
efficacy or safety concerns, and survival within 7
days after the end of therapy.
Health Care Resource Utilization
Health care resource utilization was analyzed
by assessing data obtained from the University of
Michigan Hospitals and Health Centers data
warehouse.  Mean hospital length of stay,
antifungal drug costs, total pharmacy costs, and
total hospital costs were compared between the
L-AmB and voriconazole groups.  Analyses were
limited to costs from the time empiric antifungal
therapy was started until all antifungal drugs
were discontinued.  Costs associated with
antifungal drugs that were added to L-AmB or
voriconazole therapy or with drugs begun after
the discontinuation of L-AmB or voriconazole
were also collected.
Statistical Analysis
The Student t test was used for all comparisons
of continuous data between the groups.  When
normality could not be assumed, the Mann-
Whitney U test was applied.  The x2 or Fisher
exact test was used for all other comparisons
between voriconazole and L-AmB.  An a of 0.05
was applied.  Results are reported as the number
(percentage) of episodes, the mean ± SD, or the
mean dollars.  Statistical analyses were performed
using SAS, version 9.1 (SAS Institute Inc., Cary,
NC).
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Results
Patients’ Baseline Characteristics
Fifty-five patients encompassing 58 treatment
episodes met the inclusion criteria.  Twenty-six
(45%) of the episodes represented L-AmB use in
2002, and 32 (55%) represented voriconazole use
in 2003.
Table 1 summarizes the patients’ demographic
and clinical characteristics.  The two study groups
were similar with respect to all baseline clinical
characteristics.  More episodes of refractory or
relapsed acute myeloid leukemia were noted in
the L-AmB group than in the voriconazole group;
however, the difference was not significant (35%
vs 13%; p=0.061).
Effectiveness
Table 2 summarizes the effectiveness
outcomes.  No statistically significant differences
were noted between the groups in terms of the
number of episodes in which fever resolved
during neutropenia or in which a breakthrough
invasive fungal infection occurred.  Three
possible breakthrough invasive fungal infections
occurred in the L-AmB group.  In two, bron-
choalveolar lavage fluid was positive for yeast.
One proven and three possible breakthrough
invasive fungal infections were observed in the
voriconazole group.  The proven infection was a
fungal pneumonia due to Mucor species.  In all
other possible breakthrough episodes, tests of the
bronchoalveolar lavage fluid yielded negative
results.
Empiric antifungal agents were discontinued
because of a perceived lack of efficacy more often
with voriconazole than with L-AmB, but the
difference was not statistically significant.  In 20
(77%) of 26 episodes involving L-AmB use,
patients survived as long as 7 days after the end
of therapy compared with all 32 (100%) episodes
in the voriconazole group (p=0.006).  Multiple
logistic regression analysis was performed to
adjust for the high number of relapsed or
refractory episodes of acute myeloid leukemia in
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Table 1.  Demographic and Clinical Characteristics of the Patients During the 58 Episodes
L-AmB Group Voriconazole Group
Characteristic (26 episodes) (32 episodes) p Value
No. (%) of Episodes
Sex 0.596
Male 14 (54) 20 (63)
Female 12 (46) 12 (38)
Race >0.999
Caucasian 25 (96) 30 (94)
African-American 0 (0) 1 (3)
Other 1 (4) 1 (3)
Primary diagnosis
New AML 13 (50) 20 (63) 0.427
Relapsed or refractory AML 9 (35) 4 (13) 0.061
Non-Hodgkin’s lymphoma 2 (8) 3 (9) >0.999
Multiple myeloma 2 (8) 0 (0) 0.197
Othera 0 (0) 5 (16) 0.058
Systemic antifungal prophylaxis 17 (65) 18 (56) 0.592
CSF therapy 16 (62) 16 (50) 0.434
Modification of antibacterial
therapyb 15 (58) 15 (47) 0.441
Chemotherapyc 6 (23) 8 (25) >0.999
Mean ± SD
Age (yrs) 57.2 ± 16.7 48.6 ± 17.2 0.061
Body weight (kg) 77.8 ± 14.8 82.5 ± 17.1 0.364
Duration (days)
Neutropenia 10.6 ± 5.4 10.2 ± 7.4 0.331
Fever 5.1 ± 2.1 5.8 ± 3.6 0.418
CSF therapy 10.8 ± 5.4 11.4 ± 6.2 0.838
L-AmB = liposomal amphotericin B; AML = acute myeloid leukemia; CSF = colony-stimulating factor.
aOne episode each of acute promyelocytic leukemia, acute lymphocytic leukemia, chronic myeloid
leukemia, Hodgkin’s disease, and myelodysplastic syndrome.
bUp to 48 hours before the start of empiric antifungal therapy.
cIntermediate- or high-dose cytarabine for induction or reinduction.
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the L-AmB group.  The difference in survival
between the groups was still in the direction
expected and remained significant (p=0.045).
Safety
Infusion-Related Reactions
Infusion-related reactions were reported in
more L-AmB episodes than voriconazole episodes
(Table 3).  These reactions in the L-AmB group
were one episode of dyspnea, flushing, laryngo-
spasm, weakness, and dizziness and one episode
of nausea.  Premedication was administered
before 24 (92%) L-AmB infusions.
Hepatotoxicity and Nephrotoxicity
At baseline, L-AmB and voriconazole episodes
were associated with similar rates of serum
creatinine levels more than 2.0 mg/dl (4% vs 0%,
p=0.448) or hepatic enzyme levels more than 3
times baseline (15% vs 9%, p=0.691).  During
empiric antifungal therapy, the groups did not
significantly differ in the number of episodes in
which hepatic enzyme levels were elevated.
Hypokalemia, hypomagnesemia, and nephro-
toxicity occurred significantly more frequently in
L-AmB episodes than in voriconazole episodes.
Two patients in the L-AmB group required
dialysis while they were receiving empiric anti-
fungal therapy.  In both episodes, therapy with L-
AmB was not the direct cause of dialysis; however,
it contributed to worsening renal function.
Visual Disturbances
Three cases of visual disturbances were
reported in the voriconazole group versus none
in the L-AmB group; this difference was not
statistically significant (Table 3).  The visual
disturbances were two episodes of visual
hallucinations and one episode of blurred vision.
Other Adverse Reactions
Adverse reactions other than those previously
described occurred in three (12%) L-AmB
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Table 2.  Effectiveness and Composite Outcomes
L-AmB Group Voriconazole Group
Outcome (26 episodes) (32 episodes) p Value
Time to fever resolution,a
mean ± SD (days) 5.3 ± 3.9 4.9 ± 3.6 0.706
No. (%) of Episodes
Resolution of fevera while neutropenic 14 (54) 19 (59) 0.791
No breakthrough invasive fungal infectionb 23 (88) 28 (88) >0.999
No discontinuation due to prescriber’s
perceived lack of efficacy 24 (92) 24 (75) 0.160
Survivalb 20 (77) 32 (100) 0.006
Composite 7 (27) 13 (41) 0.405
L-AmB = liposomal amphotericin B.
aTemperature < 100.4°F (< 38°C) for at least 24 hours.
bWithin 7 days after the end of therapy.
Table 3.  Safety Outcomes
No. (%) of Episodes
L-AmB Group Voriconazole Group
Outcome (26 episodes) (32 episodes) p Value
Infusion-related reactions 2 (8) 1 (3) 0.582
Nephrotoxicitya 7 (27) 1 (3) 0.017
Dialysis 2 (8) 0 (0) 0.197
Hypokalemia or hypomagnesemia 5 (19) 0 (0) 0.014
Visual disturbances 0 (0) 3 (9) 0.245
Altered liver functionb 2 (8) 3 (9) >0.999
Discontinuation of therapyc 1 (4) 4 (13) 0.367
L-AmB = liposomal amphotericin B.
aSerum creatinine level greater than 1.5 times baseline at end of therapy.
bElevated alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase, or bilirubin levels.
cBecause of a documented adverse effect or a concern about an adverse effect.
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episodes and seven (22%) voriconazole episodes.
In the L-AmB group, rash, diarrhea, and nausea
were reported.  Voriconazole-treated patients
experienced rash (four episodes), diarrhea (two
episodes), or central nervous system disturbances
(one episode), which included confusion,
hallucinations other than visual hallucinations,
and instability.  Rash secondary to voriconazole
therapy was most often described as diffuse,
erythematous, and maculopapular.
Numbers of episodes in which empiric
antifungal therapy was discontinued because of
adverse effects did not significantly differ.
Composite Outcome
No significant difference was noted between
the L-AmB and voriconazole groups in the
number of episodes in which the composite
outcome was achieved (Table 2).
Health Care Resource Utilization
The mean duration of hospital stay was 32.0 ±
13.9 days for L-AmB–treated patients compared
with 29.6 ± 12.4 days for voriconazole-treated
patients (p=0.313).  Treatment durations and
costs are compared in Table 4.
Mean drug expenditures/episode for the
empiric agent alone were substantially lower in
the voriconazole group than in the L-AmB group
($1593 vs $4144).  Adjusted for the mean
duration of therapy, these costs were $153 and
$380/day for voriconazole and L-AmB,
respectively.  Mean costs of antifungal therapy
(not including the initial antifungal agent) used
in lieu of or in addition to the initial agent were
higher with voriconazole than with L-AmB
(Table 4); this result was consistent with the
finding that a switch to or the addition of an
alternative antifungal agent occurred most
frequently in the voriconazole group.  Despite the
high cost of using alternative or additional
antifungal drugs, overall mean drug expendi-
tures/episode after we accounted for all anti-
fungals used were still lower for voriconazole-
treated patients than for L-AmB–treated patients
(Table 4).  Antifungal spending accounted for
27% and 37% of total pharmacy costs in the
voriconazole and L-AmB groups, respectively.
Total hospital costs/episode were similar for
voriconazole versus L-AmB ($56,621 vs $56,495).
Comparison of Use of Empiric Antifungal Drugs
Before and After Algorithm Implementation
Figures 2 and 3 illustrate the use of L-AmB
before implementation and voriconazole after
implementation of the algorithm, respectively.
In 81% of the episodes with L-AmB occurring
before implementation of the febrile neutropenia
treatment algorithm, therapy was continued
without interruption.  In 15% of episodes, L-AmB
was discontinued, and voriconazole was started
because of adverse effects (two episodes),
possible breakthrough invasive fungal infection
(one episode), or a desire to switch to oral
antifungal therapy (one episode).  In one L-AmB
episode, combination antifungal therapy with
voriconazole was used to treat a possible
breakthrough invasive fungal infection.
After the febrile neutropenia treatment
algorithm was implemented, L-AmB was used in
five episodes.  In four of these episodes, L-AmB
was used in accordance with the algorithm in
that patients were not eligible to receive
voriconazole because of elevated hepatic enzyme
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Table 4.  Treatment Durations and Costs
L-AmB Group Voriconazole Group
Measure (26 episodes) (32 episodes)
Mean ± SD
Treatment duration (days)
Intravenous 10.9 ± 8.1 5.5 ± 4.1
Oral NA 7.1 ± 5.2
Total 10.9 ± 8.1 10.4 ± 6.5
Mean
Drug expenditure/episode ($)
Primary empiric therapy 4144 1593
Alternative or additional
antifungal therapy 2235 3624
Total 6379 5217
L-AmB = liposomal amphotericin B; NA =  not applicable.
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concentrations (three episodes) or therapy with
gemtuzumab (one episode).
In 53% of voriconazole episodes, therapy was
continued without interruption.  In 34% of
episodes, voriconazole was discontinued and L-
AmB was started.  Primary reasons for these
changes were a perceived lack of efficacy in seven
cases, followed by adverse effects in two and
breakthrough invasive fungal infection in two.  In
four (13%) episodes, combination antifungal
therapy with L-AmB (three episodes) or
caspofungin (one episode) was used.  In two
cases, combination therapy was used to treat a
possible breakthrough invasive fungal infection.
Discussion
Invasive fungal infections are among the
leading causes of death in patients with
neutropenic cancer and pose diagnostic and
therapeutic challenges.  Empiric antifungal
therapy has become the standard of care for
patients with neutropenia and fever that persists
despite broad-spectrum antibacterial therapy.1, 14–16
Although empiric antifungal therapy is now
widely accepted, the antifungal of choice remains
controversial.17–22 Results of two small studies
helped to establish amphotericin B deoxycholate
as the standard against which all other antifungal
agents would later be compared.23, 24 Since then,
several agents have been evaluated for their
comparative efficacy in the empiric treatment of
fungal infections during febrile neutropenia.2, 4,
25–32 The United States Food and Drug Adminis-
tration has approved four agents—amphotericin
B deoxycholate, L-AmB, itraconazole, and
caspofungin—for this indication.33–36
Although voriconazole was evaluated in one of
the largest studies of febrile neutropenia, its
relative efficacy compared with that of L-AmB
remains highly debated.  The only randomized
controlled study to compare voriconazole with L-
AmB in the setting of neutropenic fever did not
demonstrate that voriconazole was noninferior to
L-AmB.4 No significant difference was observed
in the overall response rate (as evaluated by
using a composite outcome) between L-AmB–
and voriconazole-treated patients (30.6% vs
26.0%, 95% confidence interval for the difference
-10.6–1.6).  However, post hoc analyses of the
individual outcome variables demonstrated a
significantly lower occurrence of breakthrough
invasive fungal infections with voriconazole than
with L-AmB (8 vs 21, p=0.02).  This finding was
controversial.18, 37 However, coupled with the
established effectiveness of voriconazole for
treating invasive fungal infections, the finding
stimulated interest in voriconazole as a feasible
alternative to L-AmB.10, 38
Despite the few episodes involved in our
retrospective analysis, we observed statistically
and clinically significant differences in relevant
effectiveness, safety, and economic outcomes for
voriconazole compared with L-AmB in a clinical
practice setting.  Whether implementation of the
febrile neutropenia treatment algorithm alone
influenced these outcomes cannot be entirely
excluded.39 Rates of breakthrough invasive
fungal infections at our institution were similar
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Figure 2. Empiric use of liposomal amphotericin B (L-
AmB) before implementation of the febrile neutropenia
treatment algorithm.  aA third episode in which L-AmB was
discontinued because of an adverse reaction was reported,
but it did not lead to a switch to another antifungal agent.
bThis was one of three (all classified as possible)
breakthrough invasive fungal infections reported in the L-
AmB group; therapy with L-AmB was continued in the
remaining episode.
26 episodes
Switch to another
antifungal drug:
4 episodes
No change
in therapy:
21 episodes
Add another
antifungal drug:
1 episode
Adverse
reactions:
2 episodesa
Breakthrough
invasive fungal
infection:
1 episodeb
Switch to oral
antifungal
therapy:
1 episode
Breakthrough
invasive fungal
infection:
1 episodeb
Figure 3. Empiric use of voriconazole after implementation
of the febrile neutropenia treatment algorithm.  aSeven of
eight episodes in which the drug was discontinued because
of a perceived lack of efficacy.  bThese were two of four
(three possible, one proven) breakthrough invasive fungal
infections reported in the voriconazole group.
32 episodes
Switch to another
antifungal drug:
11 episodes
No change
in therapy:
17 episodes
Add another
antifungal drug:
4 episodes
Perceived lack
of efficacy:
7 episodesa
Adverse
reactions:
2 episodes
Breakthrough
invasive fungal
infection:
2 episodesb
Breakthrough
invasive fungal
infection:
2 episodesb
Additional
empiric
coverage:
2 episodes
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to those reported in the literature.  An association
between prophylactic use of voriconazole and an
increased frequency of zygomycosis has been
suggested.40 This suggestion is notable in so far
as the only proven breakthrough invasive fungal
infection in our voriconazole group was due to
Mucor species.  However, whether this event was
related in any way to the exposure to voricona-
zole is unknown.
The rate of premature discontinuation due to a
perceived lack of efficacy was highest in the
voriconazole group.  This finding may reflect lack
of prescriber confidence in voriconazole given
the limited clinical experience with this agent
when the new algorithm was being implemented.
The relatively frequent switch to or the addition
of an alternative antifungal agent in the voricona-
zole group increased expenditures on other
antifungals in voriconazole-treated patients
($3624) compared with L-AmB–treated patients
($2235).  In the converse, the lack of alternative
antifungals, such as voriconazole and caspo-
fungin, for empiric therapy before implemen-
tation of the algorithm in January 2003 may have
contributed to the low rates of discontinuation in
the L-AmB group.  In addition, our algorithm
recommended a switch to L-AmB after only 72
hours of treatment with voriconazole for patients
who had persistent fever.  This period may have
been too short to enable the clinician to assess
antifungal effectiveness, and it may have con-
tributed to the relatively high rates of premature
discontinuation in the voriconazole group.
Consistent with the safety profile of the agents,
infusion-related reactions, elevated serum
creatinine concentrations, and electrolyte
disturbances were most common in the L-AmB
group.  Although elevated hepatic enzyme levels
and visual disturbances were reported in the
voriconazole group, they occurred in few
patients.  Visual disturbances contributed to the
discontinuation of voriconazole in two episodes.
The adverse effects that led to one drug
discontinuation in the L-AmB group were serious
infusion-related reactions.
Based on these results, we continue to use this
algorithm at our institution for the empiric
treatment of fungal infections in adult patients
with hematologic cancer and febrile neutropenia.
However, the use of voriconazole as the primary
empiric antifungal agent is not without its
limitations, which include the potential for
serious cytochrome P450–based drug-drug
interactions and the development of infections
from Zygomycetes species.  Voriconazole lacks
activity against these pathogens,40 which are
associated with a high mortality rate in
immunocompromised patients with prolonged
neutropenia.
The noninferiority of caspofungin to L-AmB
was demonstrated in a clinical trial similar to that
conducted to compare L-AmB and voriconazole.32
However, caspofungin has not replaced voricona-
zole in the febrile neutropenia treatment algorithm
at this time because it does not confer advantages
over voriconazole with regard to ease of adminis-
tration or institutional acquisition cost.  In addition,
outcomes data suggesting the superiority of either
agent from a safety or effectiveness perspective in
the setting of febrile neutropenia are not yet
available.
Study Limitations
The retrospective and observational nature of
this study limited our ability to control for bias;
however, the similarities between the L-AmB and
voriconazole groups in demographic and clinical
characteristics suggest that the groups were well
balanced with respect to their risks of acquiring
invasive fungal infections.1, 41 Furthermore, an
internal registry of all chemotherapy regimens
that patients with acute leukemia received at our
institution suggests that treatment outcomes
directly attributable to these regimens have
remained relatively unchanged over the past 4
years.  Antifungal prophylaxis or modifications to
antibacterial therapy made immediately before
the start of empiric antifungal therapy likely had
minimal confounding effects given that these
events occurred in similar numbers of L-AmB
and voriconazole episodes.
Although we based our outcome measures on
well-established definitions of efficacy and safety
used in previous studies of empiric antifungal
therapy, assessment of these outcomes is
particularly challenging in a retrospective study.42
Given the rarity of breakthrough invasive fungal
infections, an unrealistically large number of
patients are often required to achieve adequate
statistical power to demonstrate significant
differences between agents with regard to this
outcome.  Also, in the retrospective setting,
confirmation of a breakthrough invasive fungal
infection depended on the availability of culture
results, which may not have been obtained before
we evaluated for the presence of infection (i.e., 7
days after discontinuation of the empiric
antifungal agent).  Use of defervescence as an
outcome measure is also limited because of its
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lack of specificity for occult fungal infection, and
it can be highly variable given the arbitrary
nature of when it is assessed relative to the
administration of antifungal therapy.
We attempted to address some of these
limitations by incorporating a composite
outcome into our effectiveness measures and by
not relying solely on one end point to define
clinical effectiveness.  Furthermore, despite the
small sample size, statistically significant
differences between the L-AmB and voriconazole
groups were observed for certain effectiveness
and safety outcomes.  A study larger than ours is
unlikely to reveal statistically significant
differences between these agents given the
similar responses seen in the L-AmB and
voriconazole groups, especially with respect to
defervescence and breakthrough invasive fungal
infections.  We chose not to report any post hoc
power calculations to determine if our study had
adequate power to reveal differences between the
groups.  The reason was because this practice has
widely been discouraged as a means of explaining
nonsignificant results.43, 44 Differences between
antifungal agents in the setting of febrile
neutropenia may not be evident if patients have a
low risk of acquiring an invasive fungal infection
at baseline; the results may reflect only the
futility of both agents.42 However, the
characteristics of our population (i.e., patients
with hematologic malignancies and prolonged
neutropenic fever who were primarily
undergoing highly immunosuppressive induction
chemotherapy) suggest that this was not the case
in our study. Ours was the subset of patients
considered to be at highest risk for invasive
fungal infection.1, 41
In addition, clinicians should exercise caution
when extrapolating our results to different insti-
tutions and patient populations (i.e., recipients of
hematopoietic stem cell transplants). These
results are specific to our patient population and
may vary given differences among institutions in
terms of patients’ clinical and demographic
characteristics, chemotherapy and study protocols,
patterns of antibiotic use, strategies for antifungal
prophylaxis, and commonly encountered
pathogens.
Conclusion
This retrospective analysis examined our
institution’s febrile neutropenia treatment
algorithm that incorporates voriconazole as the
primary empiric antifungal agent to treat febrile
neutropenia in adults; the analysis demonstrated
that voriconazole had effectiveness outcomes
comparable to those of L-AmB, and was asso-
ciated with lower costs and fewer adverse effects.
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